Equities analysts expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to report $0.22 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Supernus Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.18 and the highest estimate coming in at $0.24. Supernus Pharmaceuticals reported earnings of $0.08 per share during the same quarter last year, which would indicate a positive year over year growth rate of 175%. The business is expected to issue its next earnings report after the market closes on Tuesday, May 9th.
On average, analysts expect that Supernus Pharmaceuticals will report full year earnings of $1.28 per share for the current fiscal year, with EPS estimates ranging from $0.95 to $1.50. For the next year, analysts expect that the firm will post earnings of $1.71 per share, with EPS estimates ranging from $1.35 to $2.03. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Supernus Pharmaceuticals.
SUPN has been the topic of a number of analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Supernus Pharmaceuticals in a report on Tuesday, April 11th. Stifel Nicolaus increased their price objective on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, April 3rd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday, January 12th. Finally, Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, February 4th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $28.83.
In related news, CFO Gregory S. Patrick sold 54,000 shares of the stock in a transaction dated Monday, April 24th. The shares were sold at an average price of $32.37, for a total value of $1,747,980.00. Following the sale, the chief financial officer now owns 54,221 shares of the company’s stock, valued at approximately $1,755,133.77. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 11,806 shares of the stock in a transaction dated Monday, April 24th. The stock was sold at an average price of $32.59, for a total transaction of $384,757.54. Following the completion of the sale, the vice president now directly owns 45,500 shares in the company, valued at approximately $1,482,845. The disclosure for this sale can be found here. 6.10% of the stock is owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in the company. Pacad Investment Ltd. purchased a new stake in Supernus Pharmaceuticals during the fourth quarter worth $124,000. Fortaleza Asset Management Inc. bought a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $160,000. State of Alaska Department of Revenue boosted its position in Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock valued at $173,000 after buying an additional 170 shares during the last quarter. Stevens Capital Management LP bought a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $201,000. Finally, First Citizens Bank & Trust Co. bought a new position in Supernus Pharmaceuticals during the first quarter valued at approximately $208,000. 94.94% of the stock is currently owned by institutional investors and hedge funds.
Supernus Pharmaceuticals (NASDAQ:SUPN) traded down 0.62% on Wednesday, reaching $32.05. 617,246 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $31.33 and its 200 day moving average price is $25.98. Supernus Pharmaceuticals has a 1-year low of $15.20 and a 1-year high of $34.05. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 18.25 and a beta of 1.89.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com